{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-021242","form_type":"8-K","ticker":"MOVE","cik":"0001734750","company_name":"Corvex, Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.352572+00:00","generated_at":"2026-06-17T23:01:38.158692+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Movano Health Q4 2022 net loss $7.9M; progressing toward summer 2023 Evie Ring launch","bullets":["Net loss of $7.9M ($0.24/sh) in Q4 2022 vs $6.3M ($0.19/sh) in Q4 2021; no revenue in either period.","Cash and equivalents $10.8M at Dec 31, 2022; completed $7.5M public offering in Q1 2023.","Evie Ring on track for summer 2023 launch; second beta program with global athletic apparel and medical device firms.","Plan to file first 510(k) for heart rate and SpO2 clearance this spring after successful hypoxia trial (2% SpO2 margin of error).","Issued 9 new U.S. patents (21 total) for non-invasive blood pressure and glucose monitoring; first clinical studies imminent."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-021242","json":"https://secwatch.observer/filing/0001213900-23-021242.json","markdown":"https://secwatch.observer/filing/0001213900-23-021242.md","text":"https://secwatch.observer/filing/0001213900-23-021242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1734750/000121390023021242/0001213900-23-021242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1734750/000121390023021242/ea175393-8k_movanoinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:01:38.158692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b22dfb2e47660a4d39cd6889e4e2c8ad9504b670","claim":"Corvex, Inc. reported the three months and year ending December 31, 2022 results: net income a net loss attributable to common stockholders of $7.9 million, or a loss of $(0.24) per basic and diluted share, in the, EPS net loss attributable to common stockholders of $30.3 million or $(0.92) per share, compared with a net loss attributabl.","evidence_excerpt":"On March 20, 2023, Movano Inc. announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1734750/000121390023021242/0001213900-23-021242-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and year ending December 31, 2022"},{"label":"Net income","value":"a net loss attributable to common stockholders of $7.9 million, or a loss of $(0.24) per basic and diluted share, in the"},{"label":"EPS","value":"net loss attributable to common stockholders of $30.3 million or $(0.92) per share, compared with a net loss attributabl"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}